Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand

Puma Biotechnology

06/08/2026 21:35

Corrects adj EPS figure to $0.19 from $0.20 in KD table

Overview
U.S. cancer drug maker's Q2 product revenue rose yr/yr on higher NERLYNX demand
Q2 adjusted EPS rose yr/yr
Company raised 2026 revenue and net income guidance on increased NERLYNX demand

Outlook
Puma raises 2026 net product revenue guidance to $205–209 mln from $202–206 mln
Company lifts 2026 net income forecast to $17–20 mln from $16–19 mln
Puma expects third-quarter 2026 total revenue of $56–59 mln

Result Drivers
NERLYNX DEMAND - Co said higher Q2 product revenue was driven by increased demand for NERLYNX
R&D EXPENSES - Co said higher operating costs were mainly due to increased clinical trial expense for alisertib
COMMERCIAL EXECUTION - Management attributed improved results to commercial execution and progress in clinical development

Company press release: ID:nBw8RncCSa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Total Revenue
 
$56.50 mln
 
Q2 Adjusted EPS
Beat
$0.19
$0.04 (1 Analyst)
Q2 EPS
 
$0.16
 
Q2 Adjusted Net Income
Beat
$10.10 mln
$1.90 mln (1 Analyst)
Q2 Net Income
 
$8.20 mln
 

Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.00, about 37.4% below its August 5 closing price of $7.99
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 16 three months ago

Reuters Recommended Reads
Aug 6 - Cancer drugmaker Genmab's H1 revenue rises, lifts FY outlook
Aug 6 - CG Oncology Q2 net loss widens on higher R&D costs
Aug 6 - ALX Oncology Q2 net loss narrows on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)